NGDC - GSA for Human

HRA001206

HRA001206.xlsx

Title:

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab

Release date:

2021-09-07

Description:

Circular HER2 RNA (circHER2) encoded a novel protein, HER2_103. Unexpectedly, while HER2 mRNA and protein were barely detected, circ_HER2/HER2_103 was expressed in about 30% TNBC clinical samples. Circ_HER2/HER2_103 positive TNBC patients harbored worse overall prognosis than circ_HER2/HER2_103 negative patients.Knockdown circ_HER2 inhibited TNBC cells proliferation, invasion and tumorigenesis in vitro and in vivo, suggesting the critical role of circ_HER2/HER2_103 in TNBC tumorigenicity. Mechanistically, HER2_103 promoted homo/hetero dimerization of epidermal growth factor receptor (EGFR)/HER3, sustained AKT phosphorylation and downstream malignant phenotypes. Furthermore, HER2_103 shared most of the same amino acid sequences as HER2 CR1 domain which could be antagonized by Pertuzumab, a clinical used HER2 antibody. Pertuzumab markedly attenuated in vivo tumorigenicity of circ_HER2/HER2_103 expressing TNBC cells but showed no effects in circ_HER2/HER2_103 negative TNBC cells.

Data Accessibility:

Controlled access Request Data

BioProject:

PRJCA005969

Study type:

Disease Study

Disease name:

triple-receptor negative breast cancer

Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.

DAC NO.:

HDAC000783

DAC name:

Nu Zhang lab Data Access Committee

Contact person:

Zhang Nu

Email:

zhangnu2@mail.sysu.edu.cn

Description:

Control the Nu Zhang lab's data access in NGDC

Aspera Command Line